Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals
International Journal of Toxicology · 2024
DOI: 10.1177/10915818241247527 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Toxicology, 2024. Verfasst von Bindhu S Jatoth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. Hauptthemen laut MEDLINE: Streptococcus salivarius. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Unique Biotech Limited Hyderabad, India.
Abstract (Originalsprache)
Streptococcus salivarius is a common, harmless, and prevalent member of the oral microbiota in humans. In the present study, the safety of S. salivarius UBSS-01 was evaluated using in silico methods and preclinical and clinical studies. In an acute toxicity study, rats were administered with 5 g/kg (500 × 10 9 CFU) S. salivarius UBSS-01. The changes in phenotypic behaviors and hematological, biochemical, electrolytes, and urine analyses were monitored. No toxicity was observed at 14 days post-treatment. The no observable effects limit (NOEL) of S. salivarius UBSS-01 was >5 g/kg in rats. In a 28-day repeat dose toxicity study, rats were administered S. salivarius UBSS-01 once daily at doses of 0.1, 0.5, and 1 g/kg (10, 50, and 100 billion CFU/kg, respectively) body weight. S. salivarius UBSS-01 did not influence any of the hematology parameters and clinical chemistry parameters in plasma and serum samples after 28-day repeated administration. No structural abnormality was observed in the histological examination of organs. Whole genome analysis revealed the absence of virulence factors or genes that may transmit antibiotic resistance. In the double-blind study with 60 human participants (aged 18–60 years), consumption of S. salivarius UBSS-01 for 30 days was found to be safe and results were comparable with placebo treatment These findings indicate that S. salivarius UBSS-01 may be safe for human consumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
- Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G. Nagara, India.
- Department of Otorhinolaryngology and Head & Neck Surgery, Adichunchanagiri Institute of Medical Sciences, B. G. Nagara, India.
ORCID-Profile: Manoj P Dandekar
Förderung
- Unique Biotech Limited Hyderabad, India
Zitieren
APA
Jatoth, B. S., Rahman, Z., Dandekar, M. P., Venkataraman, R., Shivalingegowda, R. K., & Manuel, G. G. (2024). Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals. International Journal of Toxicology. https://doi.org/10.1177/10915818241247527
Vancouver
Jatoth BS, Rahman Z, Dandekar MP, Venkataraman R, Shivalingegowda RK, Manuel GG. Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals. International Journal of Toxicology. 2024. doi:10.1177/10915818241247527
BibTeX
@article{Jatoth2024,
author = {Jatoth, Bindhu S and Rahman, Ziaur and Dandekar, Manoj P and Venkataraman, Rajesh and Shivalingegowda, Ravi K and Manuel, Gloriya G},
title = {Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals},
journal = {International Journal of Toxicology},
year = {2024},
doi = {10.1177/10915818241247527}
}
EUVIMED